Daniel Brims Analyst PerformanceSenior Biotech Research Analyst at Lake Street CapitalDaniel Brims is a stock analyst at Lake Street Capital in the healthcare sector, covering 7 publicly traded companies. Over the past year, Daniel Brims has issued 7 stock ratings, including and buy recommendations. While full access to Daniel Brims' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Brims' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings13 Last 12 YearsBuy Recommendations100.00% 13 Buy RatingsCompanies Covered7 Unique Companies Ratings Distribution13RatingsDistribution of strong buy, buy, hold, and sell ratings by Daniel Brims.RatingPercentageCount Strong Buy0.0%0 ratings Buy100.0%13 ratings Hold0.0%0 ratings Sell0.0%0 ratingsthe majority (100.0%) have been Buy recommendations.Best & Worst CallsBest Call0000.0%BHCAug 2014Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CMRXAug 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ85.7% of companies on NASDAQ6 companiesNYSE14.3% of companies on NYSE1 companyDaniel Brims, an analyst at Lake Street Capital, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare7 companies100.0%Daniel Brims of Lake Street Capital specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY5 companies71.4%PHARMACEUTICALS2 companies28.6% Daniel Brims' Ratings History at Lake Street Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKYNBKyntra Bio9/17/2026Initiated Coverage$7.61$41.00Buy$0.0000.00% ROIKYNBKyntra Bio9/17/2026Initiated Coverage$7.10$41.00Buy$0.0000.00% ROISPRBSpruce Biosciences9/17/2026Initiated Coverage$54.16$149.00Buy$0.0000.00% ROIALGSAligos Therapeutics5/28/2026Initiated Coverage$5.60$45.00Buy$0.0000.00% ROIVKTXViking Therapeutics5/28/2026Initiated Coverage$31.66$89.00Buy$0.0000.00% ROIKURAKura Oncology4/14/2026Initiated Coverage$8.72$23.00Buy$0.0000.00% ROIKURAKura Oncology4/14/2026Initiated Coverage$9.14$23.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
